2nd potential Alzheimer's drug can slow disease by a few months but with safety risk

Another experimental Alzheimer's drug can modestly slow patients' inevitable worsening by about four to seven months, according to researchers.

FILE - A sign for Eli Lilly & Co. sits outside their corporate headquarters in Indianapolis on April 26, 2017.

We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

13WHAM /  🏆 256. in US

United States Latest News, United States Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Second Alzheimer's drug in pipeline can slow the disease by a few months but with safety riskNew research shows another experimental Alzheimer's drug can modestly slow patients' inevitable worsening.
Read more »

Second Alzheimer's drug in pipeline can slow the disease by a few months but with safety riskAnother experimental Alzheimer's drug can modestly slow patients' inevitable worsening — by about four to seven months, researchers reported Monday.
Read more »

Second Alzheimer's drug in pipeline can slow the disease by a few months but with safety riskNew research shows another experimental Alzheimer's drug can modestly slow patients' inevitable worsening.
Read more »

Gene-Editing Tools Pave Way for New Alzheimer's TreatmentsTwo new studies using CRISPR gene editing offer potential new treatments for Alzheimer's disease.
Read more »